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Aggressive angiomyxoma, ﬁrst described by Steeper and Rosai in
1983 (Steeper and Rosai, 1983) and now called “deep angiomyxoma”
according to the World Health Organization classiﬁcation, is a rare
benign slow-growing hypocellular soft tissue neoplasm composed
of cytologically bland stellate and spindle-shaped cells in a myxoid
background, with a conspicuous vascular component.
Clinical misdiagnosis, most commonly as a Bartholin cyst, is a
common problem, reported in as many as 82% of cases (Smith et al.,
1991). Although aggressive angiomyxoma is benign, it is locally inﬁl-
trative with a high rate of recurrence (71% at 3 years, in one study),
with intervals from 9 to 180 months. The high rate of recurrence is
thought to be secondary to inadequate primary excision (Peihai
et al., 2011).
Cytogenetic studies of myxomas are few. To date, abnormal cyto-
genetic ﬁndings have been reported for only twelve cases of aggres-
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myxoma arising in the vulval wall of a 32-year-old woman.Case report
An otherwise healthy 32-year-old female was seen at the
Women's hospital, School of Medicine, ZheJiang University, com-
plaining of a mass on the right vulva. The mass had gradually in-
creased in size in a year period. Gynecologic history was
unremarkable, with menarche at age 15 and regular cyclic menses.
Physical examination was normal with the exception of an exophytic
polypoid mass measuring 7×6×5 cm in the right vulva region
(Fig. 1). Computerized tomography and magnetic resonance imaging
of the abdomen and pelvis were performed. A soft tissue mass
extending from the right labiummajus was identiﬁed. Differential di-
agnostic considerations included a complicated Bartholin gland cyst,
or a soft tissue sarcoma. A ﬁne-needle biopsy of the mass was
obtained. Histopathologic examination of the biopsy specimen dem-
onstrated a hypocellular lesion consisting of cytologically bland
spindle-shaped cells in a myxoid background. No signiﬁcant nuclear
pleomorphism or mitotic activity was present. The spindle cells
were immunoreactive for desmin, SMA, CD10, CD34, VIM, ER and PR.
Excision of the mass was accomplished without difﬁculty; the
base of the lesion was well demarcated, and a deep dissection was
not necessary. The specimen was examined in the operating room
and consisted of a soft tissue mass with overlying skin that measured
10×6×3 cm in total. A portion of this specimen was submitted for
cytogenetic analysis. The procedure was well tolerated. One year
later the patient was well without evidence of recurrence.
Histologically, the lesion was a hypocellular myxoid neoplasm
composed of a monotonous population of stellate and spindle cells
with occasional admixed mast cells. Extracellular ground substance
associated with focal microcystic degeneration was present. There
was a prominent vascular component, composed predominantly of
capillaries and venules, which were focally dilated and congested,
with lumenal ﬁbrin thrombi. Necrosis, cellular atypia, and mitotic ﬁg-
ures were not present.
Immunohistochemistry revealed strong positivity for vimentin,
SM actin, desmin and CD34 were positive. Progesterone was positive
and estrogen weakly positive, and CD10 were negative.
Analysis of one hundred metaphase cells from representative
tumor tissue revealed mutation in X chromosome in thirteen cells
Fig. 1. Anatomy of vulvar aggressive angiomyxioma.
40 X.X. Jiang et al. / Gynecologic Oncology Reports 2 (2012) 39–41(45,X(Kenny-Moynihan et al., 1996)/47,XX +21(Peihai et al., 2011)/
47,XXX(Smith et al., 1991)/48,XXXX(Peihai et al., 2011)) and a nor-
mal complement in the remaining eighty seven. A representative
karyotype is presented in Fig. 2. Analysis of one hundred metaphase
cells from the peripheral blood sample revealed similar mutation in
X chromosome complement.
Discussion
The immunohistochemical study of our case revealed positive
progesterone receptors and weakly positive estrogen indicating a
high rate of relapse. Fishman et al. (Sun and Li, 2010) described a
case of a 37-year-old woman with a diagnosis of aggressive angio-
myxoma who was weakly estrogen-positive and progesterone-
negative, and relapsed during pregnancy. On the other hand,
Htwe et al. (Kenny-Moynihan et al., 1996) found that a 41-year-
old woman diagnosed as having aggressive angiomyxoma during
pregnancy was with positive progesterone receptors and negativeFig. 2. Mutation karyotype in X chromosome in thirteenestrogen receptors. Recent reports suggest a role for hormone ma-
nipulation in the management of these tumors. Sun (Nilsson et al.,
2006) reported a 31-year-old woman, postsurgery, a GnRH agonist
(3.75 mg triptorelin) was injected intramuscularly every month
for 3 months to prevent tumor recurrence and no relapse has
been observed. Whether treatment is with surgery, hormone ther-
apy or both, it is clear that aggressive angiomyxoma requires close,
long-term follow-up to monitor for disease recurrence and that
the individualization of each case is essential for adequate man-
agement. Because of weakly estrogen-positive, this patient
rejected GnRH agonist injection, we have followed-up this patient
for two years but no relapse was found, and longer monitoring was
recommended (Fig. 3).
Aggressive angiomyxoma is rare and benign in vulvar soft connec-
tive tissue. Cytogenetic abnormalities have been identiﬁed in twelve
cases of aggressive angiomyxoma to date (Rawlinson et al., 2008).
Abnormalities of chromosome X were detected in two of these
cases. In this case of aggressive angiomyxoma of the vulva region ofcells(45,X[5]/47,XX+21[3]/47,XXX[2]/48,XXXX[3]).
Fig. 3. Vascular Component were immunoreactive for ACT, CD10, CD34, Desmin, ER and PR.
41X.X. Jiang et al. / Gynecologic Oncology Reports 2 (2012) 39–41an otherwise healthy 32-year-old female, mutation of an X chromo-
some was seen (45,X/47,XX+21/47,XXX/48,XXXX). The woman
bore a 6-year-old son, whose peripheral blood sample was normal.
This ﬁnding is of interest with respect to the observation of the loss
of X chromosome in another clonally aberrant myxomas cytogeneti-
cally described. The latter was normal in peripheral blood
chromosome.
Cytogenetic abnormalities involving chromosome 12 are reported
in eight cases of aggressive angiomyxoma. Chromosome 12 is
reported to be rearranged with chromosome (Tsuji et al., 2007). An-
other article reported chromosome 15 rearranged with chromosome
25 (Kazmierczak et al., 1995). Chromosomal aberrations involving
the breakpoint region 12q14-15 are frequently seen in aggressive
angiomyxoma (McCluggage et al., 2006). In this case, chromosome
21 rearranging with chromosome X was seen.
In summary, the present case of aggressive angiomyxoma demon-
strated a 45,X/47,XX+21/47,XXX/48,XXXX. Further studies are need-
ed to determine if sex chromosome mutation or translocation of
chromosome 21 is characteristic of aggressive angiomyxoma in gen-
eral. Recent reports suggest a role for hormone manipulation in the
management of these tumors. It has been reported that a recurrent
aggressive angiomyxoma can be treated using GnRH agonists, which
makes it possible to avoid further destructive surgery. Given the pos-
itive progesterone and weakly positive estrogen receptor status of the
tumor described here, we don't consider hormonal treatments in the
case of a future relapse. One year later the patient was well without
evidence of recurrence.Conﬂict of interest statement
The authors have no conﬂicts of interest to disclose.
References
Kazmierczak, B., Wanschura, S., Meyer-Bolte, K., Caselitz, J., Meister, P., Bartnitzke, S.,
Van de Ven, W., Bullerdiek, J., 1995. Cytogenic and molecular analysis of an aggres-
sive angiomyxoma. Am. J. Pathol. 147, 580–585.
Kenny-Moynihan, Mary B., Hagen, Jedd, Richman, Brett, McIntosh, David G., Bridge,
Julia A., 1996. Loss of an X chromosome in aggressive angiomyxoma of female
soft parts: a case report. Cancer Genet. Cytogenet. 89, 61–64.
McCluggage, W.G., Jamieson, T., Dobbs, S.P., Grey, A., 2006. Aggressive angiomyxoma of
the vulva: dramatic response to gonadotropin-releasing hormone agonist therapy.
Gynecol. Oncol. 100, 623–625.
Nilsson, M., Mertens, F., Hoglund, M., Mandahl, N., Panagopoulos, I., 2006. Truncation
and fusion of HMGA2 in lipomas with rearrangements of 5q32/q33 and 12q14/
q15. Cytogenet. Genome Res. 112 60e6.
Peihai, Zhang, Kun, Song, LiLi, Feng Geng, Jie, Li, Ruifen, Dong, Tingguo, Zhang, kong,
Beihua, 2011. Aggressive angiomyxoma with massive ascites. Gynecologic Oncolo-
gy Case Report. . Available online 16 September.
Rawlinson, Neil J., West, William W., Nelson, Marilu, Bridge, Julia A., 2008. Aggressive
angiomyxoma with t(12;21) and HMGA2 rearrangement: report of a case and re-
view of the literature. Cancer Genet. Cytogenet. 181, 119–124.
Smith, H.O., Worrell, R.V., Smith, A.Y., Dorin, M.H., Rosenberg, R.D., Bartow, S.A., 1991.
Aggressive angiomyxoma of the female pelvis and perineum: review of the litera-
ture. Gynecol. Oncol. 42, 79–85.
Steeper, T.A., Rosai, J., 1983. Aggressive angiomyxoma of the female pelvis and perine-
um: report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm.
Am. J. Surg. Pathol. 7, 463–475.
Sun, N.X., Li, W., 2010. Aggressive angiomyxoma of the vulva: case report and literature
review. J. Int. Med. Res. 38, 1547–1552.
Tsuji, T., Yoshinaga,M., Inomoto, Y., Taguchi, S., Douchi, T., 2007. Aggressive angiomyxoma
of the vulva with a sole t(5;8)(p15;q22) chromosome change. Int. J. Gynecol. Pathol.
26, 494–496.
